David McIntosh: How European Plasma Policy Shapes Global Access to Life-Saving Therapies
David McIntosh, Founder and Chair of United Plasma Action, shared Expresso’s post on LinkedIn:
“This excellent post highlights a stubborn problem that has afflicted the European Union throughout this Century – doing great damage, not only to European Healthcare but to Healthcare globally.
In the field of vital plasma-derived medicines (of which there’s a fatal global shortage)
European institutions lounge luxuriously in a self-important but utterly delusional feeling of superior morality, based on pseudo-ethical notions about the sanctity of ‘Substances of Human Origin‘.
Less self-indulgent philosophers recognize that the important thing about life-saving plasma-derived medicines is not their origin, but their destination.
They are produced for one purpose and for one purpose only – to provide patients with the treatments they need.
All over the World, rare disease sufferers are going through untold trauma and succumbing to an early death, simply due to a lack of plasma-derived medicines.
One would sincerely expect therefore that every Healthcare organization in the World would be doing its best to help increase the global plasma harvest – but what is Europe doing … ?
For instance …
- what is the EU doing?
- what is it’s SUPPLY team doing?
- what is the European Blood Alliance doing?
- what contribution is being made by the International Plasma and Fractionation Association?
The sad fact is that they are all misguidedly inhibiting progress towards improving the plasma harvest, both in Europe and globally – to the deep detriment of patients everywhere – detriment and death.
That’s what’s genuinely unethical.
It really does have to stop.”
Expresso shared a post on LinkedIn:
“Fragility.
Portugal spends 100 million euros a year on medicines made from plasma and imports 89 percent of the raw material, mainly from the USA.
Experts warn of the ethical, financial and geopolitical risks of this insufficiency.
Read more.”
Stay updated with Hemostasis Today.
-
Jul 2, 2026, 21:54Robย Maloney: Rare Disease Requires Relational Care
-
Jul 2, 2026, 21:53Quintijn Bonnez: How ADAMTS13 Conformation May Predict Early Relapse and Guide Pre-Emptive Therapy
-
Jul 2, 2026, 21:52Emina Curic: Improving the Understanding of Factor V Leiden in Everyday Clinical Practice
-
Jul 2, 2026, 21:49Lee Peter Bee: The Plastic in Your Blood Is Sabotaging Your Stem Cells
-
Jul 2, 2026, 21:49Atef Ahmed: The Lethal Triad and Damage Control Philosophy
-
Jul 2, 2026, 19:40Minoo Ahmadinejad: Improving the Recognition of Women and Girls With Hemophilia
-
Jul 2, 2026, 19:26Dhinesh Selvaraju: FDA Expands Access to HYMPAVZI in Hemophilia
-
Jul 2, 2026, 19:13Syed Fahad Hussain: Not Every Low Platelet Count Tells the Same Story
-
Jul 2, 2026, 18:59Indu Thakur: Supporting Blood Donation Through Public Awareness in MSBT